Shares of molecular diagnostics company BillionToOne (BLLN) slid 6% in pre-market trading after Fuzzy Panda Research published a critical short-seller report. The report alleges improper billing practices, undisclosed regulatory scrutiny, and weaknesses in clinical claims .
Key allegations include:
- Tennessee Medicaid inquiry in 2024 following 11 tips, referred to Medicaid Fraud Control Division.
- Alleged use of 'unlisted' CPT codes paying ~10x standard rates.
- Questionable billing for once-in-a-lifetime genetic carrier screening alongside 88% of NIPTs in Michigan Medicaid data.
Fuzzy Panda holds a short position. BillionToOne has not yet responded to the allegations .
BillionToOne shares slide in pre-market trading following short-seller report
STREETINSIDER.COMNov 18, 2:19 PM UTC
0
